Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$4.34 - $5.84 $167,432 - $225,301
38,579 Added 7.72%
538,579 $3.15 Million
Q3 2022

Nov 14, 2022

SELL
$4.27 - $7.2 $426,999 - $720,000
-100,000 Reduced 16.67%
500,000 $3.35 Million
Q2 2022

Aug 15, 2022

BUY
$2.8 - $6.36 $145,348 - $330,147
51,910 Added 9.47%
600,000 $2.53 Million
Q4 2021

Feb 14, 2022

BUY
$2.69 - $4.22 $134,500 - $211,000
50,000 Added 10.04%
548,090 $1.73 Million
Q2 2021

Aug 16, 2021

BUY
$3.77 - $5.24 $568,783 - $790,564
150,871 Added 43.45%
498,090 $2.1 Million
Q4 2020

Feb 16, 2021

SELL
$9.48 - $12.84 $1.83 Million - $2.48 Million
-193,135 Reduced 35.74%
347,219 $4.39 Million
Q3 2020

Nov 16, 2020

BUY
$8.67 - $10.82 $325,740 - $406,518
37,571 Added 7.47%
540,354 $5.31 Million
Q2 2020

Aug 14, 2020

BUY
$7.8 - $11.52 $396,887 - $586,172
50,883 Added 11.26%
502,783 $5 Million
Q1 2020

May 15, 2020

BUY
$5.98 - $13.09 $796,906 - $1.74 Million
133,262 Added 41.82%
451,900 $3.99 Million
Q4 2019

Feb 14, 2020

BUY
$5.71 - $9.22 $62,239 - $100,498
10,900 Added 3.54%
318,638 $2.94 Million
Q2 2019

Aug 14, 2019

BUY
$9.44 - $13.12 $881,403 - $1.23 Million
93,369 Added 43.56%
307,738 $0
Q1 2019

May 15, 2019

BUY
$12.07 - $17.54 $1.44 Million - $2.09 Million
119,369 Added 125.65%
214,369 $0
Q4 2018

Feb 14, 2019

SELL
$11.25 - $16.17 $3.07 Million - $4.42 Million
-273,243 Reduced 74.2%
95,000 $1.19 Million
Q3 2017

Nov 14, 2017

BUY
$13.91 - $15.31 $5.12 Million - $5.64 Million
368,243
368,243 $5.43 Million

Others Institutions Holding CNCE

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0

About CONCERT PHARMACEUTICALS, INC.


  • Ticker CNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,934,600
  • Description
  • Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...
More about CNCE
Track This Portfolio

Track Alyeska Investment Group, L.P. Portfolio

Follow Alyeska Investment Group, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alyeska Investment Group, L.P. with notifications on news.